On this page

hydrocortisone and acetic acid

hydrocortisone and acetic acid otic · Solution

Prescription ANDA TE AT RLD Official labelling
Informational index, not medical advice. Content is reproduced from public FDA and NLM data. Always confirm against the manufacturer's current prescribing information. Report adverse events to FDA MedWatch.

Overview

Brand name
hydrocortisone and acetic acid
Generic name
hydrocortisone and acetic acid otic
Dosage form
Solution
Route
Auricular (Otic)
Marketing category
ANDA · ANDA
Labeler
Saptalis Pharmaceuticals, LLC
Product type
Human Prescription Drug
DEA schedule
Not scheduled
Active ingredients
6
NDC product codes
3
Packages
3
Data completeness
77% of corroborating sources present

Active ingredients

Source: NDC Directory
Active ingredients and strengths as listed in the NDC Directory.
Ingredient Strength RxCUI Monograph
Acetic Acid 20 mg/mL 197305 View
Acetic Acid 20.75 mg/mL 197305 View
Acetic Acid 20.8 mg/mL 197305 View
Hydrocortisone 10 mg/mL 604449 View
Hydrocortisone 10.375 mg/mL 604449 View
Hydrocortisone 10.4 mg/mL 604449 View

Forms, strengths and routes

Source: NDC Directory
Dosage form
Solution
Route of administration
Auricular (Otic)
Presentations
6

Pharmacologic classes are listed in the class section below.

Pharmacologic class

Source: NDC Directory
Established pharmacologic classes (EPC), mechanisms of action (MoA), chemical structures (CS) and physiologic effects (PE).
Class Type Browse
Corticosteroid Hormone Receptor Agonists [MoA] MoA All 215 members
Corticosteroid [EPC] EPC All 215 members

Regulatory status

Source: Drugs@FDANDC Directory
Application number
012770
Application type
ANDA · Abbreviated New Drug Application
Approval date
June 23, 1961
Sponsor
SAPTALIS PHARMS
Products on application
1
Submissions recorded
20
Products approved under application 012770.
Product Trade name Form Strength Ingredient Status TE Flags
012770-001 VOSOL HC SOLUTION/DROPS ACETIC ACID, GLACIAL; HYDROCORTISONE Prescription AT RLD RS

Therapeutic equivalence

Source: Orange Book
TE code
AT
Reference Listed Drug
Yes
Reference Standard
Yes

What this rating means: Therapeutically equivalent — bioequivalence demonstrated (topical dermatological products)

Codes beginning with “A” indicate products the FDA considers therapeutically equivalent. Codes beginning with “B” indicate bioequivalence has not been established. See methodology.

Approval history

Source: Drugs@FDA
Most recent submissions on application 012770.
Type No. Action Status Date Review
Supplement 33 Labeling Approved December 3, 2024 Standard
Supplement 25 Manufacturing (CMC) Approved October 16, 1997 Standard
Supplement 24 Labeling Approved July 29, 1997 Standard
Supplement 22 Manufacturing (CMC) Approved December 21, 1995 Standard
Supplement 21 Labeling Approved August 1, 1990 —
Supplement 20 Manufacturing (CMC) Approved August 1, 1990 Standard
Supplement 19 Manufacturing (CMC) Approved September 15, 1988 Standard
Supplement 18 Manufacturing (CMC) Approved September 15, 1988 Standard
Supplement 16 Labeling Approved June 29, 1988 —
Supplement 15 Manufacturing (CMC) Approved August 26, 1986 Standard
Supplement 14 Manufacturing (CMC) Approved June 24, 1985 Standard
Supplement 10 Labeling Approved August 14, 1984 —
Supplement 13 Manufacturing (CMC) Approved April 5, 1984 Standard
Supplement 11 Manufacturing (CMC) Approved February 4, 1983 Standard
Supplement 8 Manufacturing (CMC) Approved December 4, 1978 Standard
Supplement 9 Labeling Approved July 25, 1978 —
Supplement 6 Manufacturing (CMC) Approved April 7, 1976 Standard
Supplement 5 Manufacturing (CMC) Approved June 2, 1975 Standard
Supplement 4 Supplement Approved July 16, 1974 Standard
Original application 1 Type 4 - New Combination Approved June 23, 1961 Standard

Review documents

  • 0 · Supplement · March 14, 2025
  • 0 · Supplement · December 4, 2024
  • 0 · Supplement · July 18, 2016
  • 0 · Supplement · July 18, 2016

Prescribing information

Source: openFDA Drug Labeling

Reproduced verbatim from the Structured Product Labeling submitted to the FDA (effective 20250707). This is the manufacturer's labelling text, not a summary and not advice.

HUMAN PRESCRIPTION DRUG · 20250707 HUMAN PRESCRIPTION DRUG · 20250425

Indications and Usage

openFDA Drug Labeling

INDICATIONS AND USAGE: For the treatment of superficial infections of the external auditory canal caused by organisms susceptible to the action of the antimicrobial, complicated by inflammation.

Dosage and Administration

openFDA Drug Labeling

DOSAGE AND ADMINISTRATION: Carefully remove all cerumen and debris to allow Hydrocortisone and Acetic Acid to contact infected surfaces directly. To promote continuous contact, insert a wick of cotton saturated with Hydrocortisone and Acetic Acid into the ear canal; the wick may also be saturated after insertion. Instruct the patient to keep the wick in for at least 24 hours and to keep it moist by adding 3 to 5 drops of Hydrocortisone and Acetic Acid every 4 to 6 hours. The wick may be removed after 24 hours but the patient should continue to instill 5 drops of Hydrocortisone and Acetic Acid 3 or 4 times daily thereafter, for as long as indicated. In pediatric patients, 3 to 4 drops may be sufficient due to the smaller capacity of the ear canal.

Contraindications

openFDA Drug Labeling

CONTRAINDICATIONS Hypersensitivity to hydrocortisone and acetic acid otic solution or any of the ingredients; herpes simplex, vaccinia and varicella. Perforated tympanic membrane is considered a contraindication to the use of any medication in the external ear canal.

WARNINGS: Discontinue promptly if sensitization or irritation occurs.

Adverse Reactions

openFDA Drug Labeling

ADVERSE REACTIONS: Stinging or burning may be noted occasionally; local irritation has occurred very rarely. To report SUSPECTED ADVERSE REACTIONS, contact Saptalis Pharmaceuticals, LLC at 1-833-727-8254 or FDA at 1-­800-FDA-1088 or www.fda.gov/medwatch .

Description

openFDA Drug Labeling

DESCRIPTION Hydrocortisone and Acetic Acid Otic Solution, USP contains Hydrocortisone (1%) and acetic acid, glacial (2%) in a propylene glycol vehicle containing benzethonium chloride (0.02%), citric acid (0.2%), propylene glycol diacetate (3%) and sodium acetate (0.015%). Acetic acid has a molecular formula of CH 3 COOH with molecular weight of 60.05. The structural formula is: Hydrocortisone is a Synthetic Steroid used as an anti-inflammatory and antipruritic agent. Its chemical name is Pregn-4-ene-3,20-dione, 11, 17, 21-trihydroxy-, (11β)-. Hydrocortisone has a molecular formula of C 21 H 30 O 5 with molecular weight 362.46. The structural formula is: Hydrocortisone and acetic acid is available as a non-aqueous otic solution buffered at pH (2.0 to 4.0) for use in the external ear canal. Chemical Structure Chemical Structure

How Supplied / Storage and Handling

openFDA Drug Labeling

HOW SUPPLIED Hydrocortisone 1% and acetic acid 2% otic solution is available in 10 mL plastic, controlled dropper tip bottle. 10 mL bottle NDC 51672-3007-1 Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. Protect from freezing. Keep container tightly closed.

Adverse event reports

Source: openFDA FAERS
123,956
FAERS reports mentioning this drug
as of 2026-09-25T03:42:24+00:00
A report count is not a risk measure. FAERS accepts voluntary and mandatory reports without establishing causation, and reporting is influenced by how widely a drug is used, how long it has been marketed, and media attention. FDA states that reports “do not prove that the drug caused the event”. Compare rates, not totals.

Attributed to this product's most-reported active ingredient: HYDROCORTISONE. Combination products with more than six active ingredients are not attributed, because a report count summed across a long ingredient list measures the list, not the medicine.

Recalls

Source: FDA Enforcement
Drug recall enforcement reports associated with this product.
Classification Reported Firm Reason Status
Class III November 15, 2023 Taro Pharmaceuticals Inc. Failed Impurities/Degradation Specifications:Out-of-Specification result for Hydrocortisone related impurity and slightly lower than the established level of the Hydrocortisone Assay obtained during stability testing. Terminated

Packaging and NDCs

Source: NDC Directory
Every National Drug Code package associated with this medication. The NDC is the identifier used for dispensing, billing and pharmacovigilance in the United States.
Package NDC Product NDC Labeler Description Marketing start
0713-0849-09 0713-0849 Cosette Pharmaceuticals, Inc. 1 BOTTLE in 1 CARTON (0713-0849-09) / 10 mL in 1 BOTTLE February 1, 2024
71656-064-10 71656-064 Saptalis Pharmaceuticals, LLC 1 BOTTLE, DROPPER in 1 CARTON (71656-064-10) / 10 mL in 1 BOTTLE, DROPPER February 23, 2024
51672-3007-1 51672-3007 Sun Pharmaceutical Industries, Inc. 1 BOTTLE in 1 CARTON (51672-3007-1) / 10 mL in 1 BOTTLE April 28, 2005
0713-0849 0713-0849 Cosette Pharmaceuticals, Inc. — February 1, 2024
71656-064 71656-064 Saptalis Pharmaceuticals, LLC — February 23, 2024
51672-3007 51672-3007 Sun Pharmaceutical Industries, Inc. — April 28, 2005

Sources for this page

Every dataset that contributed a fact to this page.
Dataset Agency Used for
NDC Directory FDA Identity, ingredients, strengths, forms, routes, labelers, packages
Drugs@FDA FDA Application, sponsor, submissions, review documents, marketing status
Orange Book FDA Therapeutic equivalence codes, reference drug flags, patents, exclusivity
Drug Labeling FDA / NLM Prescribing information reproduced above
FAERS FDA Adverse event report counts
Enforcement FDA Recall records

Generated September 25, 2026 · 12 sections on this page.